[(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid
| Title | Journal |
|---|---|
| The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. | Future oncology (London, England) 20150101 |
| Ixazomib for the treatment of multiple myeloma. | Expert opinion on investigational drugs 20150101 |
| An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. | OncoTargets and therapy 20140101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Molecular mechanisms of acquired proteasome inhibitor resistance. | Journal of medicinal chemistry 20121213 |
| Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. | Cancer research 20100301 |
| Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. | Leukemia 20070401 |
| Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). | Angewandte Chemie (International ed. in English) 20050919 |